论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
PD-1 抑制剂纳武单抗(nivolumab)与放疗相结合成功治疗难治性原发性纵隔大 B 细胞淋巴瘤患者:一份病例报告和文献回顾
Authors Yan Z, Yao ZH, Yao SN, Xia QX, Wang HY, Chu JF, Song M, Zhao S, Liu YY
Received 15 March 2020
Accepted for publication 8 July 2020
Published 27 July 2020 Volume 2020:12 Pages 6311—6316
DOI https://doi.org/10.2147/CMAR.S254007
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Xueqiong Zhu
Abstract: Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we treated a refractory PMBCL patient, who did not respond to salvage chemotherapy, with combined nivolumab and radiotherapy. The patient achieved a complete remission with mild adverse reactions and has survived without relapse 2 years after treatment.
Keywords: primary mediastinal large B-cell lymphoma, immunotherapy, radiotherapy, nivolumab
